The purpose of this study is to evaluate the safety of linear and macrocyclic gadolinium-based contrast agents for patients with mild to moderate renal insufficiency. The study will compare the incidence of adverse events of gadodiamide and gadoteric Acid Meglumine Salt for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging.
According to the requirements of the study, 600 cases of patients with mild to moderate renal insufficiency were enrolled. Gadodiamide and Gadoteric acid meglumine salt were used for enhanced MRI. Observe the adverse reactions within 60 minutes of using the gadolinium contrast agents; follow up by telephone at 3, 6, 12, and 24 months after the inspection. The primary endpoint is the incidence of the various adverse events, and the secondary endpoints are changes of serum creatinine and inflammatory factors (TNF-α, hs-CRP, IL-6) before and after CE-MRI, patient skin examination and evaluation (evaluation of relevant indicators of skin biopsy).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
600
Gadodiamide Injection(OMNISCAN™)
Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
Lishui Central Hospital
Lishui, Zhejiang, China
RECRUITINGThe incidence of various adverse events
Time frame: From the date of contrast injection to the incidence of adverse events, assessd up to 60 minutes
The incidence of various adverse events
Time frame: From the date of contrast injection to the incidence of adverse events, assessd up to 3 months
The incidence of various adverse events
Time frame: From the date of contrast injection to the incidence of adverse events, assessd up to 6 months
The incidence of various adverse events
Time frame: From the date of contrast injection to the incidence of adverse events, assessd up to 12 months
The incidence of various adverse events
Time frame: From the date of contrast injection to the incidence of adverse events, assessd up to 24 months
Changes of serum creatinine before and after CE-MRI at 3 days
Time frame: From the date of contrast injection to the changes of serum creatinine before and after CE-MRI, assessed up to 3 days
Changes of TNF-α before and after CE-MRI at 3 days
Time frame: From the date of contrast injection to the changes of TNF-α before and after CE-MRI, assessed up to 3 days
Changes of hs-CRP before and after CE-MRI at 3 days
Time frame: From the date of contrast injection to the changes of hs-CRP before and after CE-MRI, assessed up to 3 days
Changes of IL-6 before and after CE-MRI at 3 days
Time frame: From the date of contrast injection to the changes of IL-6 before and after CE-MRI, assessed up to 3 days
Evaluation of relevant indicators of skin biopsy
proliferation of fibroblasts in subcutaneous tissue, thickening of collagen fiber bundles
Time frame: From the date of contrast injection to the clinical manifestations appear, assessed up to 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.